

## LEGISLATIVE PROPOSALS

**Mandatory Legislative Proposals****Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Research.**

Codified in Section 330B of the PHS Act, this Program began in FY 1998 with a funding level of \$30.0 million per year over 5 years. In December 2000, the Program was renewed to increase the FY 2001 and 2002 levels to \$100.0 million and to extend the FY 2003 level at \$100.0 million of mandatory funds. In December 2002, the Program was extended and increased to \$150.0 million per year for FY 2004-2008. The Program has subsequently been extended multiple times at this annual level of \$150.0 million. For FY 2024 and FY 2025, the Program was extended in P.L. 118-15, P.L. 118-22, P.L. 118-35, P.L. 118-42, P.L. 118-158, and P.L. 119-4 for a combined total funding of \$314.8 million over those two years. No funding is provided after FY 2025 under current law.

The FY 2026 President's Budget proposal would reauthorize the NIH Special Diabetes Program for Type 1 Diabetes Research at an annual amount of \$159.0 million for FY 2026. The reauthorization would help facilitate planning of research projects and enable the continuation of the program's unique, extraordinarily collaborative, and scientifically comprehensive research strategy to prevent, treat, and cure type 1 diabetes. The reauthorized funding level would restore some of the lost purchasing power of the program after remaining flat for 20 years prior to a 5 percent increase in FY 2024-2025.

[THIS PAGE INTENTIONALLY LEFT BLANK]